Overview

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Status:
Recruiting
Trial end date:
2025-10-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations and other mutations.
Phase:
Phase 2
Details
Lead Sponsor:
Taiho Oncology, Inc.